Obesity treatments catch drugmakers’ eyes as sales seen soaring
Novo Nordisk’s days of being alone to market an approved weight-loss drug are numbered as firms position themselves to split the market that’ll reach USD 30bn by 2030.
By Robert Langreth and Emma Court, bloomberg
Three years ago, drugmakers and laboratories around the world responded to the pandemic with Covid-19 vaccines. Now that the urgency has faded, they’re collectively turning attention to an older pandemic: obesity.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly predicts possible launch of obesity drug in 2023
For subscribers
